A pilot study of adjuvant chemotherapy with cisplatin and irinotecan for High grade pulmonary neuroendocrine carcinona (Large cell neuroendocrine carcinoma and small cell lung cancer)
Phase 2
- Conditions
- High grade pulmonary neuroendocrine carcinona (Large cell neuroendocrine carcinoma and small cell lung cancer)
- Registration Number
- JPRN-UMIN000001319
- Lead Sponsor
- Department Thoracic Oncology, National Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) prior radiotherapy 2) active concomitant malignancy 3) with uncontrolled pleural/pericardial effusion 4) with interstitial pneumonia or pulmonary fibrosis as determined by chest x-ray 5) watery diarrhea 6) intestinal obstruction or paralysis 7) symptomatic brain metastasis 8) with serious complications .cardiac failure, stenocardia, and myocardial infarction within the previous 3 months .uncontrolled diabetes mellitus and hypertension .uncontrolled infection 9) pregnant or lactating women 10) psychological disease deemed unacceptable for inclusion to the study 11) with severe drug allergy 12) doctor's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method